1. Long-lasting effects of sublingual immunotherapy according to its duration: A 15-year prospective study 
Maurizio Marogna, MD, Igino Spadolini, MD, Alessandro Massolo, BS, Giorgio Walter Canonica, MD, Giovanni Passalacqua, MD 
Journal of Allergy and Clinical Immunology 
Volume 126, Issue 5, Pages (November 2010)
DOI: /j.jaci
Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2. Fig 1 Patients’ disposition and dropouts.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3. Fig 2
Mean monthly SMSs (means and SDs) throughout the 15 years of the study in patients in the SLIT3 (A), SLIT4 (B), and SLIT5 (C) groups. The duration of SLIT treatment is indicated by arrows at the bottom. The asterisks indicate a significant difference versus the control group.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4. Fig 3
Monthly drug intake scores throughout the study in the SLIT3 (blue line), SLIT4 (red line), SLIT5 (green line), and control (black line) groups. The SLIT treatments are indicated by colored horizontal arrows. The asterisks indicate a significant difference between the control group and the 3 SLIT groups.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5. Fig 4
Percentage of patients with at least 1 new skin sensitization in the SLIT3 (blue line), SLIT4 (red line), SLIT5 (green line), and control (black line) groups. The asterisk indicates the significant difference versus the control group.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6. Fig 5
Percentages of nasal eosinophils throughout the study in the SLIT3 (blue line), SLIT4 (red line), SLIT5 (green line), and control (black line) groups. SLIT treatments are indicated by colored horizontal arrows. The asterisks indicate a significant difference between the control group and the 3 SLIT groups. NS, No significant difference between the control group and the SLIT3 group.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

7. Fig 6
Methacholine PD20 (in micrograms) throughout the study in the SLIT3 (blue line), SLIT4 (red line), SLIT5 (green line), and control (black line) groups. The duration of SLIT treatments is indicated by colored horizontal arrows. The asterisks indicate a significant difference between the control group and the 3 SLIT groups. NS, No significant difference between the control and SLIT3 groups.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions